Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: EMN stock price vs ECL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ECL's multiple
Needs ECL P/E.
Implied fair value · at EMN's multiple
Needs EMN P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
16 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
EASTMAN CHEMICAL CO · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ECOLAB INC. · implied price per share
Bear
$44.93
Base
$57.49
Bull
$73.86
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe EMN can reaccelerate revenue growth and sustain margins closer to ECL’s profitability profile, then the stock could warrant a higher multiple; otherwise, EMN looks more fairly valued near its DCF and historical band than its ECL-implied price suggests.
EMN trades at a steep valuation discount to ECL, with P/E of 17.9x versus 38.9x, P/S of 1.0x versus 4.9x, and EV/EBITDA of 9.8x versus 21.1x. However, EMN’s implied price of $159.64 sits far above both its current price of $73.50 and its historical band, while its DCF range of $61.17 to $82.76 suggests limited fundamental upside at current levels.
Supporting Metrics
